<DOC>
	<DOCNO>NCT00326144</DOCNO>
	<brief_summary>The purpose study demonstrate superior efficacy Quetiapine fumarate sustain release ( SEROQUEL ) compare placebo use mono-therapy treatment Major Depressive Disorders PLEASE NOTE : Seroquel SR Seroquel XR refer formulation . The SR designation change XR consultation FDA .</brief_summary>
	<brief_title>Efficacy Safety Quetiapine Fumarate Sustained Release ( SEROQUEL SR ) Treatment Major Depressive Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Patient able provide write informed consent begin study related procedure Patient document clinical diagnosis major depressive disorder Patient able understand comply requirement study , judge study investigator Patients history noncompliance judge study investigator Patients know lack response previous treatment quetiapine Patients participate clinical trial within 4 week randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>MDD</keyword>
	<keyword>Depression</keyword>
</DOC>